AI Quick Summary
🔍 Meet the Residents Across Our SI Parks! 🔎🚀We are happy to share that @Engimmune Therapeutics AG and @Swiss Technology Innovation Center CSEM, both @SIP Basel Main Campus site residents, have decided to collaborate, supported by a grant from @Innosuisse. This collaboration aims to expedite the identification of safe and effective soluble T-cell receptor (TCR) drugs using CSEM's high-throughput microfluidics technology.🔬 Powerful Collaboration: Leveraging CSEM's expertise in microtechnologies and droplet microfluidics, Engimmune is set to revolutionize the identification of TCR candidates with enhanced affinity, potency, and safety profiles.🌐 Cutting-edge Technologies: Engimmune's proprietary platform technologies, combining genome editing, deep sequencing, functional screening, and AI, provide a head start in the pursuit of highly targeted and potent 'off-the-shelf' soluble TCRs.💡 Reducing Development Risks: The collaboration focuses on ruling out potentially harmful TCRs early in the process, ensuring resources are dedicated to candidates with breakthrough potential for treating solid tumor cancers.🌍 International Showcase: Catch Engimmune's executive team presenting these groundbreaking technologies at the Biotech Showcase in San Francisco on January 8.Read More: 🔗 https://ethz.ch/en/industry/industry/news/data/2023/11/redirecting-immune-cells-against-cancer.html🔗 https://www.prnewswire.com/news-releases/engimmune-therapeutics-strikes-fast-forward-micro-fluidics-collaboration-with-swiss-innovator-csem-302013321.html
Post Description
๐ Meet the Residents Across Our SI Parks! ๐
๐We are happy to share that @Engimmune Therapeutics AG and @Swiss Technology Innovation Center CSEM, both @SIP Basel Main Campus site residents, have decided to collaborate, supported by a grant from @Innosuisse. This collaboration aims to expedite the identification of safe and effective soluble T-cell receptor (TCR) drugs using CSEM's high-throughput microfluidics technology.
๐ฌ Powerful Collaboration: Leveraging CSEM's expertise in microtechnologies and droplet microfluidics, Engimmune is set to revolutionize the identification of TCR candidates with enhanced affinity, potency, and safety profiles.
๐ Cutting-edge Technologies: Engimmune's proprietary platform technologies, combining genome editing, deep sequencing, functional screening, and AI, provide a head start in the pursuit of highly targeted and potent 'off-the-shelf' soluble TCRs.
๐ก Reducing Development Risks: The collaboration focuses on ruling out potentially harmful TCRs early in the process, ensuring resources are dedicated to candidates with breakthrough potential for treating solid tumor cancers.
๐ International Showcase: Catch Engimmune's executive team presenting these groundbreaking technologies at the Biotech Showcase in San Francisco on January 8.
Read More:
๐ https://ethz.ch/en/industry/industry/news/data/2023/11/redirecting-immune-cells-against-cancer.html
๐ https://www.prnewswire.com/news-releases/engimmune-therapeutics-strikes-fast-forward-micro-fluidics-collaboration-with-swiss-innovator-csem-302013321.html